Šīs tīmekļa vietnes satura kvalitātes uzlabošanai un pielāgošanai lietotāju vajadzībām tiek lietotas sīkdatnes - tai skaitā arī trešo pušu sīkdatnes. Turpinot lietot šo vietni Jūs piekrītat sīkdatņu lietošanai.
Sales of Olainfarm in February Increase by 33%
Emitents Olainfarm, AS (213800WCG52W62ENOP27)
Veids 2.2. Iekšējā informācija
Valoda EN
Statuss Publicēts
Versija
Datums 2018-03-19 16:15:32
Versijas komentārs
Teksts

 

March 19, 2018

 

Sales of Olainfarm in February Increase by 33%

 

 

Preliminary consolidated sales results of JSC Olainfarm for February 2018 show that sales have reached 10.69 million euros, which represents an increase by 33% compared to February 2017. The biggest sales increase was achieved in Japan, where sales grew by 6430%. Sales to Lithuania grew by 161%, sales to Georgia grew by 155%, sales to Kazakhstan grew by 118%, but sales to Belarus increased by 92%. During February 2018, the group also made significant shipments to Uzbekistan and Tajikistan. Major sales markets of Olainfarm group in February 2018 were Latvia, Russia, Belarus and Ukraine. Products of the group were sold to 35 countries.

 

February 2018, consolidated sales

Sales, thsnd. EUR

Changes to February 2017

Share in total sales

Latvia

2 773

11%

26%

Russia

2 753

5%

26%

Belarus

1 661

92%

16%

Ukraine

1 024

-3%

10%

Japan

315

6430%

3%

Kazakhstan

300

118%

3%

Lithuania

229

161%

2%

Uzbekistan

222

NA

2%

Georgia

165

155%

2%

Tajikistan

145

NA

1%

Other

1 099

62%

10%

Total

10 686

33%

100%

 

Sales numbers of daughter companies of JSC Olainfarm that provide significant impact on consolidated results show that sales of Latvijas aptieka in February 2018 reached 1.68 million euros, which is comparable to the sales volume demonstrated in February 2017. Sixty-eight pharmacies were operating during February. Sales of Silvanols during this period were 0.59 million euros, which represents an increase by 4%. Combined sales of Tonus Elast and its Russian based distributor Elast Medikl reached 0.65 million euros. Combined sales of medical companies Klīnika DiaMed and OlainMed reached 0.2 million euros, while sales of Belarus based company NPK Biotest also reached 0.2 million euros.

 

 

February 2018

Sales markets of Olainfarm

28

Sales markets of the Group

35

Number of pharmacies of Latvijas aptieka

68

Sales of Latvijas aptieka

€ 1 675 594

Combined sales of OlainMed and Klīnika DiaMed

€ 199 000

Sales of NPK Biotest

€ 199 407

Combined sales of Tonus Elast and Elast Medikl

€ 647 265

Sales of Silvanols

€ 585 302

 

According to unconsolidated preliminary results, sales of JSC Olainfarm in February 2018 reached 8.62 million euros, which represents an increase by 44% compared to the same period of 2017. Biggest sales increase was achieved in Japan, where sales grew by 6430%. Sales to Kazakhstan grew by 257%, but sales to Lithuania grew by 240%. During February 2018, JSC Olainfarm also made significant shipments to Uzbekistan and Tajikistan. Major sales markets during February were Russia, Latvia, Belarus and Ukraine. In total products of JSC Olainfarm were sold to 28 countries.

February 2018, unconsolidated sales

Sales, thsnd., EUR

Changes to February 2017

Share in total sales

Russia

2 459

8%

29%

Latvia

1 526

26%

18%

Belarus

1 427

67%

17%

Ukraine

1 024

-3%

12%

Japan

315

6430%

4%

Kazakhstan

231

257%

3%

Lithuania

225

240%

3%

Uzbekistan

222

NA

3%

Tajikistan

145

NA

2%

Germany

143

67%

2%

Other

899

149%

10%

Total

8 616

44%

100%

 

During the first two months of 2018, the consolidated sales of the group reached 19.88 million euros, which represents an increase by 16% compared to consolidated sales of two months of 2017. The biggest sales increases were achieved in Uzbekistan, where sales grew by 757%, in Japan sales grew by 332%, and in Kazakhstan, where sales grew by 124%. The major sales markets of JSC Olainfarm in two months of 2018 were Latvia, Russia, Belarus and Ukraine, products were sold in 32 countries.

 

2 months of 2018, consolidated sales

Sales, thsnd. EUR

Changes to 2 months of 2017

Share in total sales

Latvia

5 695

15%

29%

Russia

4 469

-10%

22%

Belarus

3 357

35%

17%

Ukraine

2 132

56%

11%

Kazakhstan

549

124%

3%

Uzbekistan

393

757%

2%

Lithuania

374

47%

2%

Germany

353

23%

2%

Japan

315

332%

2%

Tajikistan

208

NA

1%

Other

2 032

-17%

10%

Total

19 877

16%

100%

 

During the first two months of 2018, sales of Latvijas aptieka reached 3.7 million euros, which represents an increase by 9% compared to sales during the same period of 2017. Sales of Silvanols during two months were 1 million euros, which represents a reduction by 6% compared to two months of 2017. Combined sales of Tonus Elast and its Russian based distributor Elast Medikl in two months of 2018 reached 1.16 million euros. Combined sales of medical companies Klīnika DiaMed and OlainMed in two months of 2018 reached 0.4 million euros, while sales of Belarus based company NPK Biotest also reached 0.4 million euros.

 

2 months of 2018

Sales markets of Olainfarm

32

Sales markets of the Group

39

Sales of Latvijas aptieka

€ 3 702 114

Combined sales of OlainMed and Klīnika DiaMed

€ 396 000

Sales of NPK Biotest

€ 395 435

Combined sales of Tonus Elast and Elast Medikl

€ 1 162 517

Sales of Silvanols

€ 1 003 518

 

According to unconsolidated preliminary results, sales of JSC Olainfarm in two months of 2018 were 15.72 million euros, which represents an increase by 15% compared to the same period of 2017. The biggest sales increases were achieved in Uzbekistan, where sales grew by 757%, in Japan, where sales grew by 332%, and in Kazakhstan, where sales grew by 211%. Biggest sales markets of JSC Olainfarm in the first two months of 2018 were Russia, Latvia, Belarus and Ukraine. In total in two months of 2018, JSC Olainfarm sold its products to 32 countries.

 

2 months of 2018, unconsolidated sales

Sales, thsnd. EUR

Changes to 2 months of 2017

Share in total sales

Russia

3 946

-15%

25%

Latvia

3 024

21%

19%

Belarus

2 927

19%

19%

Ukraine

2 132

56%

14%

Kazakhstan

464

211%

3%

Uzbekistan

393

757%

3%

Lithuania

361

74%

2%

Germany

350

23%

2%

Japan

315

332%

2%

Tajikistan

208

NA

1%

Other

1 595

-21%

10%

Total

15 715

15%

100%

 

According to preliminary estimates, unconsolidated sales of JSC Olainfarm in 2018 might reach 96 million euros, while consolidated sales might reach 130 million euros. According to the preliminary sales numbers published here, during two months of 2018, the company has already made 16% of its unconsolidated sales estimate and 15% of its annual consolidated sales estimate.

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 45 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top-quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 50 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

Information prepared by: Salvis Lapins JSC Olainfarm Member of the Management Board Rupnicu iela 5, Olaine, Latvia, LV 2114 Phone: +371 6 7013 717 Fax: +371 6 7013 777 E-mail: Salvis.Lapins@olainfarm.lv

 

 

Pielikumi